MDX2004 is designed to activate T cells through three unique signalling pathways to enhance immune activation.

Regeneron will be responsible for funding preclinical, clinical and commercial development for any ModeX product it chooses to advance from the research pact, with ModeX eligible for milestone ...

First patient dosed in Phase 1/2a study with novel immune rejuvenator, a trispecific antibody-fusion protein Two MDX2004 abstracts accepted for ...

Potential assets would target multiple biological pathways in a single molecule Total value of the partnership potentially exceeds $1 billion if ...

US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) has entered a license and collaboration deal with OPKO Health’s (Nasdaq: ...

Regeneron and ModeX Therapeutics have joined forces in a collaboration worth over one billion dollars to develop ...

The big-time BARDA contracts keep rolling in, this time for infectious disease biotech and Merck partner ModeX Therapeutics. The company has hauled in a $168 million contract from the Biomedical ...

ModeX Therapeutics Inc., an OPKO Health company, announced the formation of a Scientific Advisory Board to support the development of its immunology and oncology pipeline, which includes ...

Road Town, British Virgin Islands--(Newsfile Corp. - October 9, 2023) - LBank Exchange, a global digital asset trading platform, will list Modex (MODEX) on October 10, 2023. For all users of LBank ...

ModeX Therapeutics enters research collaboration with Regeneron to develop multispecific antibodies for select therapeutic indications: Weston, Massachusetts Thursday, October 30, ...